HRP20120228T1 - Kladribinski režim za liječenje multiple skleroze - Google Patents
Kladribinski režim za liječenje multiple skleroze Download PDFInfo
- Publication number
- HRP20120228T1 HRP20120228T1 HR20120228T HRP20120228T HRP20120228T1 HR P20120228 T1 HRP20120228 T1 HR P20120228T1 HR 20120228 T HR20120228 T HR 20120228T HR P20120228 T HRP20120228 T HR P20120228T HR P20120228 T1 HRP20120228 T1 HR P20120228T1
- Authority
- HR
- Croatia
- Prior art keywords
- cladribine
- period
- months
- pharmaceutical formulation
- administered
- Prior art date
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title claims abstract 61
- 229960002436 cladribine Drugs 0.000 title claims abstract 59
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 35
- 238000012423 maintenance Methods 0.000 claims abstract 15
- 230000002045 lasting effect Effects 0.000 claims abstract 14
- 238000009472 formulation Methods 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 6
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| PCT/EP2005/056954 WO2006067141A1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120228T1 true HRP20120228T1 (hr) | 2012-04-30 |
Family
ID=36227798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120228T HRP20120228T1 (hr) | 2004-12-22 | 2012-03-13 | Kladribinski režim za liječenje multiple skleroze |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (pl) |
| EP (6) | EP1827461B1 (pl) |
| JP (7) | JP5795456B2 (pl) |
| KR (1) | KR20070091662A (pl) |
| AR (1) | AR052830A1 (pl) |
| AU (2) | AU2005318190B2 (pl) |
| BR (1) | BRPI0517132B8 (pl) |
| CA (2) | CA3087419C (pl) |
| CY (3) | CY1112614T1 (pl) |
| DK (2) | DK2805723T3 (pl) |
| EA (1) | EA015799B1 (pl) |
| ES (1) | ES2921858T3 (pl) |
| FR (1) | FR18C1008I2 (pl) |
| HR (1) | HRP20120228T1 (pl) |
| HU (2) | HUE059133T2 (pl) |
| IL (2) | IL183930A0 (pl) |
| LT (2) | LT3332789T (pl) |
| LU (1) | LUC00064I2 (pl) |
| MX (1) | MX2007007610A (pl) |
| NO (1) | NO20073813L (pl) |
| PL (3) | PL2805723T3 (pl) |
| SG (1) | SG160391A1 (pl) |
| SI (2) | SI3332789T1 (pl) |
| WO (1) | WO2006067141A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007253254B2 (en) * | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) * | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| US10849919B2 (en) * | 2017-11-24 | 2020-12-01 | Merck Patent Gmbh | Cladribine regimen for treating progressive forms of multiple sclerosis |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| CA2208484C (en) | 1994-12-22 | 2008-09-23 | Ortho Pharmaceutical Corporation | Soluble 2-chloro-2'-deoxyadenosine formulations |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| WO2004028462A2 (en) | 2002-09-25 | 2004-04-08 | Brigham Young University, Technology Transfer Office | Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| MXPA05008998A (es) * | 2003-02-25 | 2005-10-18 | Applied Research Systems | Uso combinado de ribavirina e interferon beta en enfermedades desmielinizantes. |
| MXPA05010330A (es) | 2003-03-28 | 2006-05-31 | Ivax Corp | Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa. |
| PT1608344E (pt) * | 2003-03-28 | 2010-09-02 | Ares Trading Sa | Formulações orais de cladribina |
| AU2007253254B2 (en) * | 2006-05-24 | 2013-01-17 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es active Active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en active Active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Application Discontinuation
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja active Active
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-03-13 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I1/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120228T1 (hr) | Kladribinski režim za liječenje multiple skleroze | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| HRP20110198T1 (hr) | Indikacija doziranja progesterona u liječenju traumatske ozljede mozga | |
| WO2007047327A3 (en) | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency | |
| HRP20120382T1 (hr) | Kombinacija davanja interferona-beta i kladribina za liječenje multiple skleroze | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| CA2563058C (en) | Supportive treatment of liver disease | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| HRP20120147T1 (hr) | Titracija tapentadola | |
| BRPI0414876A (pt) | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos | |
| HRP20130071T1 (hr) | Poboljšani testosteron u gelu i naäśin primjene | |
| NO20024586L (no) | FremgangsmÕte og preparat for prevensjon av hormoninduserte ugunstige virkninger | |
| MX2009004616A (es) | Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente. | |
| WO2006068768A3 (en) | Methods and compositions for treating conditions | |
| MXPA02002681A (es) | Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer. | |
| TW200626161A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| UA102187C2 (ru) | Фармацевтическая композиция для пероральной доставки дииндолилметана | |
| UA93530C2 (ru) | Композиция c пролонгированным высвобождением активного вещества, способ ee получения и применения | |
| RU2007103306A (ru) | Композиции на основе ризедроната и способы их применения | |
| AR013739A1 (es) | Composiciones de agentes reductores de lipidos | |
| BR0308229A (pt) | Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| JP2009539916A5 (pl) | ||
| WO2008122439A3 (en) | Dr0spiren0ne/17beta-estradi0l regimen, pharmaceutical combination product and kit for performing this regimen |